Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence BioMed announced a U.S. strategic engagement initiative where executive leadership will travel to meet researchers, institutions, and government stakeholders. The visit aims to educate stakeholders on the regulatory and scientific infrastructure required to manufacture pharmaceutical-grade ibogaine under GMP standards. CEO Jody Aufrichtig submitted a letter to President Trump and HHS Secretary Robert F.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.